BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update

BioAge Labs, Inc. (NASDAQ:BIOA) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 3,744,445 shares, an increase of 87.9% from the June 15th total of 1,992,676 shares. Approximately 10.6% of the shares of the company are short sold. Based on an average daily volume of 932,909 shares, the short-interest ratio is presently 4.0 days.

Wall Street Analysts Forecast Growth

BIOA has been the subject of a number of research analyst reports. BTIG Research started coverage on shares of BioAge Labs in a report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Roth Capital began coverage on BioAge Labs in a research report on Wednesday, May 27th. They issued a “buy” rating and a $36.00 target price on the stock. Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Finally, Needham & Company LLC began coverage on BioAge Labs in a research report on Friday, March 27th. They set a “buy” rating and a $50.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, BioAge Labs has an average rating of “Moderate Buy” and an average price target of $43.50.

Institutional Investors Weigh In On BioAge Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC lifted its holdings in shares of BioAge Labs by 411.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after buying an additional 1,685,063 shares during the period. Octagon Capital Advisors LP grew its holdings in BioAge Labs by 9.4% during the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock worth $30,573,000 after acquiring an additional 150,000 shares during the period. Vanguard Group Inc. raised its position in BioAge Labs by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after acquiring an additional 93,694 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in BioAge Labs during the fourth quarter valued at approximately $13,892,000. Finally, Geode Capital Management LLC lifted its holdings in BioAge Labs by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock valued at $7,826,000 after acquiring an additional 28,646 shares during the period.

BioAge Labs Trading Up 2.9%

BIOA opened at $22.81 on Friday. BioAge Labs has a 12-month low of $4.11 and a 12-month high of $25.95. The firm has a 50 day moving average of $19.88 and a two-hundred day moving average of $19.01. The firm has a market capitalization of $1.01 billion, a PE ratio of -9.50 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.19. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. The business had revenue of $2.77 million for the quarter. As a group, analysts predict that BioAge Labs will post -2.68 EPS for the current fiscal year.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.